New research from the UVA Department of Surgery’s Tsung Research Group, published in JAMA Network Open and selected as an Editor’s Pick, provides a national evaluation of the use of histotripsy for liver tumors. UVA Surgery’s early national real-world data on an emerging cancer technology helps define how it should be incorporated thoughtfully into clinical practice.
Histotripsy is a noninvasive focused ultrasound technology cleared by the FDA in 2023. Using data from 972 patients treated across U.S. health systems, the study found that histotripsy was associated with low procedural toxicity and was performed predominantly in the outpatient setting. At the same time, a 30-day mortality rate of 11.1% underscores the importance of careful patient selection as this promising technology is incorporated into multidisciplinary cancer care.
As histotripsy adoption continues to expand, these findings from the multidisciplinary UVA Surgery research team and their collaborators highlight the need for prospective studies and evidence-based treatment pathways to help define which patients are most likely to benefit.
Read the full article in JAMA Network Open titled “Early Outcomes of Histotripsy for Liver Tumors in US Clinical Practice.” The article has received media coverage in online news platforms.
Filed Under: Research